%0 Journal Article
%A Pérez-Stachowski, Javier
%A Tortajada, Begoña
%A Del Arco, Alfonso
%A Márquez, Efrén
%A De la Torre, Javier
%A Nieto, Miriam
%A García de Lomas, José María
%A Prada, José Luis
%A García-Alegría, Javier
%A Olalla, Julián
%T Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 48 weeks.
%D 2019
%U https://hdl.handle.net/10668/26684
%X Introduction: Generic drugs are helpful to enhance the efficiency of the sanitary system. A generic coformulation of abacavir (ABC) and lamivudine (3TC) is available since 2016 in Spain. A report of our experience with its use is exposed. Methods: Patients between February 2017 and June 2017 who were taking Triumeq® were switched to the generic ABC + 3TC plus DTG. Efficacy, safety, reasons for discontinuation and costs savings were evaluated at 48 weeks. Results: Switch was made in 93 patients, with a median age of 47 years and a mean time of 12.33 years with HIV infection. Six patients (6.5%) discontinued the new ART, being toxicity of the central nervous system the most frequent reason. The effective saving derived from the change after 1 year of treatment was 151.127 €. Conclusions: The change from Triumeq® to a generic regimen of ABC + 3TC and another pill of DTG seems to be safe and efficient at 48 weeks.
%K Dolutegravir
%K HIV
%K antiretroviral treatment
%K drugs
%K generic
%K switch
%~